2016Zhonghua wuli yixue zazhiRequires access

Transplanting autologous mesenchymal stem cells in the treatment of Parkinson's disease

Dinghua Liu, Lujun Gu, Bojun Han, Qingguang Wang, Shanshan Hong, Heng Jun GAO, Meirong Wan

Open publisher page 0 citations

Abstract

Objective To explore the curative effect and safety of transplanting autologous mesenchymal stem cells to patients with Parkinson's disease. Methods Forty-two patients with Parkinson's disease were selected and randomly divided into a control group and a research group, each of 21. Both groups were given routine treatment and rehabilitation, but the research group was additionally provided with autologous bone marrow mesenchymal stem cell transplantation. Bone marrow mesenchymal stem cells were isolated from the patients, cultured and transplanted back into the patients totally 4 times at intervals of 5 to 10 days. Before the treatment and 4 weeks and 3 months later, the clinical functioning of both groups was evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS). Four weeks and 3 months after the treatment, the peripheral blood expression of vascular endothelial growth factor (VEGF) , the expression of interleukin 10 (IL-10) and the expression of CSF tumor necrosis factor alpha (TNF-α) in cerebrospinal fluid were compared between the 2 groups. Results The average UPDRS score of the research group decreased from (41.26±17.92) at four weeks to (33.67±17.77) at 3 months after the treatment, both significantly lower than before the treatment, and significantly lower than the scores of the control group at the same time points [(47.13±18.35) and (39.03±16.50)]. During the treatment, no severe adverse reactions were observed among the research group. Moreover, after the treatment the blood expression of VEGF and the expression of IL-10 in cerebrospinal fluid were significantly improved in the research group, while that of TNF-α was significantly reduced compared to before the treatment. nclusions The transplantation of autologous mesenchymal stem cells can safely promote nerve function in Parkinson's disease patients. It is worth applying in clinical practice. Key words: Bone marrow; Mesenchymal stem cells; Parkinson disease; Transplantation; Autologous transplantation

About this research paper

What this paper is about

Objective To explore the curative effect and safety of transplanting autologous mesenchymal stem cells to patients with Parkinson's disease. Methods Forty-two patients with Parkinson's disease were selected and randomly divided into a control group and a research group, each of 21. Both groups were given routine treatment and rehabilitation, but the research group was additionally provided with autologous bone marrow mesenchymal stem cell transplantation. Bone marrow mesenchymal stem cells were isolated from the patients, cultured and transplanted back into the patients totally 4 times at intervals of 5 to 10 days. Before the treatment and 4 weeks and 3 months later, the clinical functioning of both groups was evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS). Four weeks and 3 months after the treatment, the peripheral blood expression of vascular endothelial growth factor (VEGF) , the expression of interleukin 10 (IL-10) and the expression of CSF tumor necrosis factor alpha (TNF-α) in cerebrospinal fluid were compared between the 2 groups. Results The average UPDRS score of the research group decreased from (41.26±17.92) at four weeks to (33.67±17.77) at 3 months after the treatment, both significantly lower than before the treatment, and significantly lower than the scores of the control group at the same time points [(47.13±18.35) and (39.03±16.50)]. During the treatment, no severe adverse reactions were observed among the research group. Moreover, after the treatment the blood expression of VEGF and the expression of IL-10 in cerebrospinal fluid were significantly improved in the research group, while that of TNF-α was significantly reduced compared to before the treatment. nclusions The transplantation of autologous mesenchymal stem cells can safely promote nerve function in Parkinson's disease patients. It is worth applying in clinical practice. Key words: Bone marrow; Mesenchymal stem cells; Parkinson disease; Transplantation; Autologous transplantation

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To explore the curative effect and safety of transplanting autologous mesenchymal stem cells to patients with Parkinson's disease. Methods Forty-two patients with Parkinson's disease were selected and randomly divided into a control group and a research group, each of 21. Both groups were given routine treatment and rehabilitation, but the research group was additionally provided with autologous bone marrow mesenchymal stem cell transplantation. Bone marrow mesenchymal stem cells were isolated from the patients, cultured and transplanted back into the patients totally 4 times at intervals of 5 to 10 days. Before the treatment and 4 weeks and 3 months later, the clinical functioning of both groups was evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS). Four weeks and 3 months after the treatment, the peripheral blood expression of vascular endothelial growth factor (VEGF) , the expression of interleukin 10 (IL-10) and the expression of CSF tumor necrosis factor alpha (TNF-α) in cerebrospinal fluid were compared between the 2 groups. Results The average UPDRS score of the research group decreased from (41.26±17.92) at four weeks to (33.67±17.77) at 3 months after the treatment, both significantly lower than before the treatment, and significantly lower than the scores of the control group at the same time points [(47.13±18.35) and (39.03±16.50)]. During the treatment, no severe adverse reactions were observed among the research group. Moreover, after the treatment the blood expression of VEGF and the expression of IL-10 in cerebrospinal fluid were significantly improved in the research group, while that of TNF-α was significantly reduced compared to before the treatment. nclusions The transplantation of autologous mesenchymal stem cells can safely promote nerve function in Parkinson's disease patients. It is worth applying in clinical practice. Key words: Bone marrow; Mesenchymal stem cells; Parkinson disease; Transplantation; Autologous transplantation

Key concepts: Medicine, Mesenchymal stem cell, Transplantation, Bone marrow, Vascular endothelial growth factor, Surgery, Stem cell, Cerebrospinal fluid

Related papers

Back to paper searchBrowse research topicsOriginal source
Transplanting autologous mesenchymal stem cells in the treatment of Parkinson's disease — Research Paper | ScholarLens